Summer sun prevents multiple sclerosis

April 10, 2007

Still more supports the theory that vitamin D can prevent multiple sclerosis. Enjoy the sun while its there.

Multiple sclerosis (MS) is a feared disease. Many believe that sclerosis is synonymous with a life in a wheelchair, and many have heard about tragic examples of how the disease can progress. It is worth remembering that even 20 years after the emergence of the disease, 75% of patients can walk unaided. Also, the death rate for those suffering from sclerosis is not much higher than that of the rest of the population.

On the other hand, MS affects especially younger people, primarily women. It is disquieting that the frequency of this disease has increased in the last 50 years and continues to increase. Over 80,000 people in the UK suffer from MS, which at a prevalence of over 140 people per 100,000 the highest in the industrialised world.

MS is an “autoimmune” disease, which is to say a disease where the body’s immune system turns against the body itself. In the case of MS the so called myelin sheaths which coat and isolate the nerves are attacked. On average, every fourth person with MS also suffers from another autoimmune disease, for example psoriasis, arthritis, or metabolism diseases.

Can one prevent MS? It is tempting to have this thought when one notices the enormous geographic variations. In England, Denmark, Norway, Sweden, Finland, Germany, and Canada the frequency is about the same. In Greece and Turkey it is about half as common while in northern Spain and Italy the frequency lies in between that of these areas.

These and other figures support a growing belief that MS has something to do with lack of sunlight; or more accurately, lack of vitamin D, of which the sun is the most important source. Vitamin D has in studies prevented an experimental form of MS (EAE, Experimental Autoimmune Encephalitis). In countries north of a latitude of 42, corresponding to Corsica, the sun is so low during the winter months that vitamin D practically cannot be produced in the skin. The result is widespread vitamin D deficiency.

Less than half the risk
Researches from Harvard University among others analyzed the problem in more detail. They studied 257 blood tests from military personnel who contracted MS between 1992 and 2004. The blood tests were taken and frozen before these people became sick. The question was whether they had remarkably little vitamin D in their blood when compared to people who did not contract MS.

It was shown that they did. 25-OH-D, the best measure for vitamin D status, was measured in both the sick and a large number of healthy people who were randomly chosen from 7 million personnel. It was found that “high circulating levels of vitamin D are associated with a lower risk of multiple sclerosis.” Low vitamin D levels were especially risky for people under 20 years of age.

How much vitamin D is enough? When the level of 25-OH-D was at least 99 nannomol/litre serum, the risk of MS was the lowest at about 40% average. The difference was statistically certain. For comparison, levels under 50 are indicative of insufficient levels of vitamin D. Such values can be found in most people during the winter.

The theory that vitamin D prevents MS is thus strengthened. One should attempt to distance oneself from vitamin D deficiency. This is easy during the summer, but from October to April it requires, for the majority of those in our latitudes, supplements.

By: Niels Hertz MD

References:
1. Munger L et al. Serum 25-Hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832-2838.
2. MS prevalence data for selected countries: http://www.mult-sclerosis.org/prev_tab.html
3. Newsletter from Vitalrådet dec. 27. 2006

jama.ama-assn.org

Vitamin D as a Universal Remedy

September 13, 2005

Vitamin D, which most people lack in the winter and many lack in the summer, has an increasing number of roles to play. A deficiency in Vitamin D increases the risk of multiple sclerosis, several types of cancer, skin diseases, and even increased blood pressure.

Vitamin D plays an important role in the public consciousness, but even a bigger role in the minds of those who develop new medicine. Substances which are related to vitamin D are central to the treatment of many serious diseases. This is shown by a comprehensive and very well documented summary from the American pharmaceutical giant Eli-Lily.

In this summary the status and possibility of vitamin D treatment for (among others) prostate cancer, enlarged prostate, breast cancer, rheumatoid arthritis, psoriasis, leukaemia, multiple sclerosis, type I diabetes, skin cancer, hypertension, and of course osteoporosis is examined.

Here are some examples:

Multiple sclerosis (MS) is a so called autoimmune disease, which means that it is a disease where the body’s immune system turns against parts of the body itself, in this case nerve tissue. In animal models of this disease it is possible to avoid outbreaks with the help of calcitriol. Calcitriol is the active version of the vitamin and is created as needed by the body so long as the vitamin D deposits are sufficient. MS is most common in temperate countries, where the sun in relatively low in the sky and vitamin D deficiency is common.

Rheumatoid arthritis is also an autoimmune disease, but with this disease the joints are attacked by the immune system. People with small vitamin D depots more often suffer from rheumatoid arthritis and the risk is higher in temperate countries than in subtropical climes. In animals it is possible to avoid worsening of symptoms if calcitriol is given early enough.

Psoriasis is already treated with salves which contain the vitamin D containing substance calcipotirol (Daivonex), which helps at least 70% of sufferers. Sunlight also helps. Like vitamin D, calcipotirol has the ability to help cells become mature and specialized without growing uncontrolled.

Death rates from prostate cancer are lowest in sunny countries, and the risk of getting this disease is highest in men who have small vitamin D deposits. In a study prostate cancer growth was inhibited in six out of seven patients with the help of calcitriol tablets (0.5-2.5 microgram per day). This is also explained by the vitamin’s effects on the cells. Because normal prostate cell growth is also slowed, researchers also see a possibility of using such treatment for enlarged prostate.

Breast cancer and colon cancer are more common in people who do no get much sun. Both the growth and the spread of breast cancer are reduced by calcitriol in animal studies. Regarding colon cancer, increased growth has been seen in animals that were artificially given vitamin D deficiency. This cancer inhibiting property is predicted to play an important role in future treatment.

Finally, hypertension should be considered. Lack of sunlight and vitamin D in the blood are believed to contribute to high blood pressure. High blood pressure is quickly caused (in mice) by avoiding vitamin D.

All of the above illnesses have the common factor that they can be provoked by lack of sunlight, the most important source of vitamin D. They are also counteracted by vitamin D and vitamin D like substances.

One could wish that it would be possible to treat and prevent these illnesses with the active form of vitamin D, calcitriol. But this is a risky method which can lead to increase calcium levels in the blood and kidney stones. Therefore we must be content with getting vitamin D the natural way, which is to say from sunlight or by eating fatty fish, and then let the organism create calcitriol as needed.

Unfortunately at our latitudes the fours summer months from May to August are the only months where there is enough sun that we create vitamin D in the skin. Those who do not come out in the sun or are covered in clothing, do not create near enough. This makes it necessary to take vitamin D in pill form.

The task is to get enough vitamin D. This is not possible during the dark months without vitamin supplements or eating a lot of fatty fish. Deficiency creates a larger problem than many are aware.

By: Vitality Council

Reference:
Nagpal S et al. Noncalcemic actions of vitamin D receptor ligands. Endocrine Reviews 2005;26:662-87.

edrv.endojournals.org
www.iom.dk